Navigation Links
Investigational Oral Multiple Sclerosis Therapy Teriflunomide (Aubagio™(*)) Significantly Reduced Relapse Rate, Disability Progression and Disease Activity
Date:10/5/2011

PARIS, Oct. 5, 2011 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today the publication of the pivotal Phase III TEMSO study with investigational once-daily oral medication teriflunomide in The New England Journal of Medicine (NEJM).  Results showed that teriflunomide at the 14mg dosage significantly reduced the annual relapse rate, reduced disability progressions and improved several magnetic resonance imaging (MRI) measures of disease activity, including new or worsening brain lesions.  Teriflunomide has a well-characterized safety profile, with a similar proportion of trial participants reporting adverse events compared to placebo.

"The TEMSO data demonstrate the effect of teriflunomide in terms of reducing relapse rates, disability progression and Magnetic Resonance Imaging (MRI) lesions," said Dr. Paul O'Connor, Director of the MS Clinic at St Michael's Hospital, Toronto, Canada and principal investigator in the TEMSO study.  "These results, sustained over two years, provide clinically meaningful data for teriflunomide."

The two-year TEMSO (TEriflunomide Multiple Sclerosis Oral) trial involved 1,088 people with relapsing forms of MS from 126 centers across 21 countries. TEMSO is the first study from a broad clinical development program that includes more than 4,000 trial participants in 36 countries and is one of the largest and broadest clinical programs of any oral MS agent under development, with five Phase III clinical trials either completed or underway.

"The publication of the teriflunomide results in the New England Journal of Medicine is an exciting milestone as we continue the development of our product," said Dr. Elias Zerhouni, President, Global Research & Development, Sanofi. "As we continue our commitment t
'/>"/>

SOURCE Sanofi; Genzyme
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger
2. Positive Phase III Data on Bayers Investigational Drug Radium-223 Chloride Show Significant Increase in Overall Survival
3. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
4. Bayer to Present New Data Evaluating Investigational Oncology Compounds at 2011 ECCO-ESMO Congress
5. Boehringer Ingelheim Broadens Its Breast Cancer Clinical Trial Program for the Investigational Compound Afatinib
6. FDA Grants Fast Track Designation to Bayers Investigational Compound Radium-223 Chloride for the Treatment of Castration-Resistant Prostate Cancer That Has Spread to the Bone
7. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
8. Marshall Edwards Announces FDA Approval of Investigational New Drug Application for Lead Candidate ME-143
9. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
10. Positive Results for Investigational Compound Lyxumia® (Lixisenatide) Presented at American Diabetes Associations 71st Annual Scientific Sessions
11. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014  ResMed (NYSE: ... people sleep and the first company to design complete sleep ... to educate women about the importance of a good night,s ... initiative will challenge the myth that feeling tired is just ... to understand that sleep is a critical pillar of health, ...
(Date:10/1/2014)... --  Cypher Genomics, Inc., the genome informatics company, ... as chief technology officer. Ravenel has more than ... a proven track record of designing and architecting solutions ... been recognized as a top designer and architect of ... for delivering innovative products that operate at scale and ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... Sept. 16 The American,Chemistry Council is aware ... today in,the Journal of the American Medical Association ... concentrations and medical,disorders in adults. As with any ... design of a study can limit interpretation of ...
... Biotech Begins to Demonstrate Strategy to Expand NHL ... Preclinical Development Program -, BRITISH COLUMBIA, Canada, ... OTC Bulletin Board: IXSBF;, http://www.ixsbio.com ), a drug ... based on its technology, Dynamic Cross,Linking (DXL(TM)), announced ...
Cached Medicine Technology:New Bisphenol A Study Has Limited Capability to Assess Human Health Effects 2InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 2InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 3
(Date:10/1/2014)... 2014 Patients with increased inflammation, including those ... increased risk of depression. For example, a 6-month ... C virus infection causes depression in approximately 30% ... commonly known as fish oil, have a long ... of heart disease and reducing triglyceride levels. These ...
(Date:10/1/2014)... October 01, 2014 Marriagelifeinsurance.com has ... life insurance for retired couples. , Senior citizens ... financial security for their loved ones. A joint policy ... insured persons pass away. , Life insurance can ... life insurance can even be purchased online, as the ...
(Date:10/1/2014)... October 01, 2014 First Warning Systems, ... circadian cellular changes throughout the body, announced the company ... better address the company’s breadth of upcoming product releases. ... cancer screening technology. , “Our initial focus will be ... which detects abnormal circadian cellular changes over time,” said ...
(Date:10/1/2014)... Join the more than 80 golfers who ... first ever charity golf tournament to benefit Project HEAL, a ... who cannot afford treatment. The tournament will be held Monday, ... , The day-long event starts with 10:30 a.m. check-in ... dinner will begin at 5 p.m. and will include an ...
(Date:10/1/2014)... Innovations announces the upcoming airing of ... Monday, October 20, 2014 at 7:30 a.m. EST/PT via ... behind the scenes to learn about Break the Cycle’s ... the practical help and information Break the Cycle provides ... signs of abuse, how to navigate the legal system, ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... ... distribute Pluromed,s BackStop™ device, a rapid phase transition gel used in the treatment of ... ... entered into an alliance with Boston Scientific Corporation (NYSE: BSX) regarding Pluromed,s BackStop™ product, ...
... , ... California is pleased to announce its new relationship with La Maestra Community Health Centers of ... well as mammography screening reports for La Maestra and their patients. , ... Riverside, CA (PRWEB) October 8, 2009 ...
... Last Sunday, the Inland Community had one message as they ... With more than 6,000 walkers and raising more than $328,000, ... Annual Believe and Walk for the Cure was a ... , The sea of goodwill was overwhelming for the Co-Founders ...
... House and Senate leaders negotiate the final details of their ... that one provision under consideration, the Community Living Assistance Services ... Moreover, the long-term cost of this new entitlement, which could ... to produce a short-term windfall. , "The CLASS Act ...
... today announced the arrival of a new subject matter ... team member signifying continued growth of the Dallas-based health ... ) , Gregory R. Alperstein, ASA, MAAA joins the ... With more than 14 years of experience in the ...
... and mom-to-be Shannon Miller is the new spokesmom for BabyPlus®. ... and has been using BabyPlus during pregnancy to ensure her ... Now she,s sharing her experience and enthusiasm for BabyPlus ... http://www.newscom.com/cgi-bin/prnh/20091007/DE88885 ) , "We are thrilled to ...
Cached Medicine News:Health News:Pluromed, Inc. Signs Agreement with Boston Scientific 2Health News:Pluromed, Inc. Signs Agreement with Boston Scientific 3Health News:ONRAD Announces New Partnership with La Maestra Community Health Centers of San Diego, CA 2Health News:Stater Bros. Charities Collects $328,000 for the Cure in 'I Believe Walk'... Over 6,000 Participate 2Health News:Concord Coalition Warns That New Entitlement Is Not a Valid Health Care Reform Offset 2Health News:Concord Coalition Warns That New Entitlement Is Not a Valid Health Care Reform Offset 3Health News:Concord Coalition Warns That New Entitlement Is Not a Valid Health Care Reform Offset 4Health News:Continued Growth Evident With New Hire and Promotion for Lockton Dunning Benefits 2Health News:Country's Most Decorated Gymnast New Spokesmom for BabyPlus 2
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: